Please login to the form below

Not currently logged in
Email:
Password:

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients
Bristol-Myers Squibb building

Bristol-Myers Squibb has awarded nine grants worth over £3.5m to support hepatitis projects in China and India.

The grants were made through BMS' Delivering Hope initiative, which has supported more than 40 projects in China and India since 2002, and will now focus on the most vulnerable and high-risk patient populations in both hepatitis B and hepatitis C.

John Damonti, president of the BMS Foundation and VP of corporate philanthropy at BMS, said: “Delivering Hope continues to increase its focus on hepatitis B and hepatitis B in China and India, the two countries that have the highest incidence of viral hepatitis worldwide.

In China, BMS awarded grants to the Peking University Education Foundation, Hepatitis B Foundation, Wu Jieping Medical Foundation and Inno Community Development Organisation. In India, the All India Institute of Diabetes and Research, MAMTA, United Way of Mumbai and SAMARTH will receive funding.

BMS awarded an additional grant to the World Hepatitis Alliance to develop an e-learning tool that will support patient groups to raise awareness of hepatitis treatment and prevention.

It is estimated that there are 123 millions people living with hepatitis B in China and India combined, while the figure is 60 million for hepatitis C. The problem is exacerbated in these countries as awareness of the virus is low so many patients go untreated.

Despite the continued prevalence of the infection the hepatitis market has been boosted in recent years by significant developments in treatments.

gilead-sciences-sovaldi 

Gilead Sciences' Sovaldi has made more than $8.5bn in 2014 so far

This has been led by Gilead Sciences' record-breaking Sovaldi (sofosbuvir), which has revolutionised hepatitis C treatment by allowing patients an interferon-free treatment regimen.

Last month, the European Medicines Agency (EMA) recommended a further two drugs by AbbVie – Exviera (dasabuvir) and combination treatment Viekirax (ombitasvir, paritaprevir and ritonavir) – for the treatment of HCV adult patients.

There was disappointing news for BMS recently however when the FDA blocked approval for daclatasvir for in hepatitis C because the drug it was developed alongside was dropped from development by BMS.

Article by
Kirstie Pickering

5th December 2014

From: Marketing, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics